Flightpath Biosciences develops first-in-class, narrow-spectrum antibiotic therapies that target specific pathogens responsible for rare infectious diseases while minimizing disruption to the microbiome. Their approach aims to effectively eliminate harmful bacteria, such as those causing gum disease and Lyme disease, without adversely affecting beneficial microorganisms.
Funding
$8.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current broad-spectrum antibiotics can disrupt the microbiome, leading to dysbiosis and potential long-term health issues, while also increasing the risk of antibiotic resistance. Many emerging infectious and chronic diseases are driven by specific pathogens, such as spirochetes and Fusobacterium, which require targeted therapies to minimize off-target effects.
Solution
Flightpath Biosciences develops narrow-spectrum antibiotic therapies designed to target specific pathogens responsible for diseases like Lyme disease, periodontal disease, and infections associated with women's health issues and certain cancers. Their approach focuses on eliminating harmful bacteria without significantly impacting the beneficial microorganisms in the body. The company's lead candidate, FP-100, is an orally bioavailable antibiotic that inhibits protein synthesis in gram-negative spirochetes and fusobacterium via a unique transport mechanism not present in mammalian cells. Flightpath Biosciences leverages advanced drug discovery tools to identify antimicrobial therapeutic candidates, improve drug targeting and safety, reduce off-target impacts on the microbiome, speed the time-to-market and reduce the risk of antibiotic resistance.
Target Audience
The primary target audience includes individuals suffering from pathogen-driven diseases such as Lyme disease, periodontal disease, and women's health issues like endometriosis, as well as the healthcare providers who treat them.
Features
- FP-100: Orally bioavailable, narrow-spectrum antibiotic targeting spirochetes and fusobacterium
- Selective mechanism of action that inhibits protein synthesis in targeted bacteria
- Demonstrated in vitro and in vivo efficacy against standard-of-care broad-spectrum antibiotics
- Favorable microbiome profile, minimizing disruption to beneficial bacteria
- Manufacturing scale-up to clinical and commercial scale with GMP drug substance and drug product manufacturing activities
- Advanced drug discovery platform for identifying and developing additional targeted antimicrobial therapies